Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.32M | 148.98K | 2.67M | 1.61M | 1.34M | 1.69M | Gross Profit |
-103.46K | 109.47K | 1.41M | 568.44K | 526.86K | 609.91K | EBIT |
-3.98M | -3.36M | -3.36M | -4.88M | -4.22M | -3.59M | EBITDA |
-3.85M | -3.23M | -2.95M | -4.25M | -3.65M | -764.08K | Net Income Common Stockholders |
5.60M | -5.03M | -3.89M | -4.60M | -3.72M | -960.18K |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
568.25K | 749.25K | 1.10M | 1.15M | 1.01M | 834.13K | Total Assets |
1.68M | 5.68M | 5.62M | 6.13M | 5.04M | 2.76M | Total Debt |
0.00 | 9.26M | 6.86M | 4.71M | 2.25M | 169.81K | Net Debt |
-568.25K | 8.51M | 5.75M | 3.56M | 1.24M | -664.31K | Total Liabilities |
69.93K | 14.09M | 9.76M | 7.70M | 3.96M | 1.92M | Stockholders Equity |
1.61M | -10.56M | -6.52M | -3.89M | -1.49M | 836.81K |
Cash Flow | Free Cash Flow | ||||
-5.67M | -3.23M | -3.13M | -2.64M | -4.07M | -1.05M | Operating Cash Flow |
-5.62M | -3.22M | -3.04M | -2.29M | -3.94M | -955.37K | Investing Cash Flow |
9.01M | -116.14K | -107.55K | -373.55K | -166.11K | -97.38K | Financing Cash Flow |
-5.61M | 2.98M | 3.10M | 2.81M | 4.28M | 1.81M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% | |
43 Neutral | C$8.29M | ― | -813.02% | ― | ― | ― | |
42 Neutral | C$9.74M | ― | -175.45% | ― | -3.93% | -575.24% | |
41 Neutral | C$16.71M | ― | 34.47% | ― | ― | 43.45% | |
C$11.37M | ― | ― | ― | ― | |||
C$15.29M | ― | ― | ― | ― | |||
$9.02M | ― | ― | ― | ― |
Kane Biotech reported a significant increase in revenue for the first quarter of 2025, primarily from contract animal health manufacturing, despite a net loss. The company is undergoing a restructuring strategy to focus on its revyve™ product line and has implemented cost-reduction initiatives to strengthen its financial position. The departure of the CEO and subsequent legal action are notable developments, but the company remains committed to advancing its pipeline and creating long-term value for stakeholders.
Kane Biotech has successfully closed a private placement offering, raising $1.2 million through the issuance of 12 million shares to company insiders. Additionally, the company secured a $1 million unsecured loan from an insider, both transactions being classified as related party transactions. The funds will be used for working capital and general corporate purposes, potentially strengthening Kane Biotech’s financial position and operational capabilities.
Kane Biotech reported its financial results for the fourth quarter and full year 2024, showing a significant increase in revenue but a net loss for the year. The company is narrowing its strategic focus to its biofilm dispersion technology-based wound care products, particularly the revyve line, and is reorganizing its distribution approach in the U.S. market. A leadership change was also announced, with Dr. Robert Huizinga stepping in as interim CEO, following the departure of Marc Edwards.
Kane Biotech has announced the termination of its previous service agreement with Outside the Box Capital Inc. (OTBC) and the initiation of a new agreement to enhance its marketing efforts within the financial community. This change was prompted by a policy update from the TSX Venture Exchange prohibiting the issuance of shares as compensation for investor relations services. Under the new agreement, OTBC will receive a cash payment and stock options, aligning with Kane Biotech’s strategic focus on broadening its media distribution and market awareness.
Kane Biotech has received approval from the University of Miami Health System’s Internal Review Board to commence a clinical study of its DispersinB® Acne Cleanser for treating mild to moderate Acne Vulgaris. This trial, set to begin mid-year at the University of Miami Miller School of Medicine, marks a significant milestone for Kane Biotech as it continues to advance its mission of providing innovative dermatological solutions, potentially impacting millions of individuals suffering from acne.
Kane Biotech has entered into a three-year distribution agreement with Best Buy Medical Canada for its revyve™ Antimicrobial Wound Gel, following Health Canada approval in November 2024. This strategic partnership aims to expand access to the wound care solution across Canada, targeting hospitals, clinics, and long-term care facilities. The collaboration is expected to enhance patient care and outcomes while tapping into the Canadian wound care market’s financial potential.